Cingulate Inc. (CING) stock
CINGNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as CINGW
$4.72+0.97 (+25.87%)
Close on Nov 17, 2026Market cap $68.64MP/E –Yield –
Cingulate net income
Net income is the profit left for shareholders after every expense, interest and tax.
Cingulate's net income for the twelve months ending Jun 30, 2026 was -$28.80M. For fiscal 2025 it was -$22.45M. The highest annual figure on record is -$7.18M in fiscal 2020.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.45M | – |
| FY2024 | Dec 31, 2024 | -$16.56M | – |
| FY2023 | Dec 31, 2023 | -$23.53M | – |
| FY2022 | Dec 31, 2022 | -$17.68M | – |
| FY2021 | Dec 31, 2021 | -$20.71M | – |
| FY2020 | Dec 31, 2020 | -$7.18M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.87M | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.31M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.27M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.34M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.98M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.97M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.93M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.00M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.61M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.03M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.04M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.00M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.29M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.43M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.33M | – |
See a number that looks wrong?